Medicare’s New Codes For Remdesivir, Convalescent Plasma To Be Test Of Real-World, Though Not Real-Time, Data
Executive Summary
CMS’s new procedure reimbursement codes will help generate ‘critical information’ on the effectiveness of the COVID products, but will suffer from a ‘claims lag.’
You may also be interested in...
Preapproval Promotion? US FDA Commissioner Touts ‘Lifesaving’ Investigational Plasma For COVID-19
Hahn’s communications, which go far beyond the claims a sponsor could make of an investigational product, are raising new concerns about the agency’s ability to serve as a science-based regulator during the coronavirus pandemic. HHS Secretary Alex Azar and NIAID Director Anthony Fauci have also touted the lifesaving nature of plasma donations for COVID-19, even though the treatment is still unproven.
Remdesivir Distribution Improvements Among Goals Of US HHS Data Reporting Overhaul
Gilead’s COVID treatment will be the first product tracked in a system that could eventually help allocate vaccines and other therapeutics.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.